Author

P. J. Converse

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 7 Pharmacology & Toxicology· 2 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 10 Organism:mouse· 10 Research Focus:host-pathogen & immune response· 8 Research Focus:drug response / drug discovery· 6 Organism:human· 1

Frequent Co-Authors

E. Nuermberger· 10 shared D. Almeida· 5 shared N. Fotouhi· 5 shared R. Tasneen· 5 shared A. Upton· 4 shared K. Mdluli· 4 shared S.-Y. Li· 4 shared T. F. Omansen· 3 shared

Activity by Year

2018-2023 · peak 4/yr

Co-Author Collaboration Network

10 top collaborators · 38 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

10 shared papersMicrobiology

E. Nuermberger

Mutual co-authors in cluster

Author profile →

10 papers

Recent·Most cited

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model

S.-Y. Li, P. J. Converse, F. Betoudji, J. Lee, K. Mdluli, A. Upton, N. Fotouhi, E. Nuermberger

This study evaluates new tuberculosis treatments in mice, finding that replacing bedaquiline with TBAJ-587 reduces relapse, while replacing linezolid with TBI-223 has no significant effect.

bioRxiv · Jan 10, 2023 · PreprintMicrobiology

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

E. Nuermberger, M. S. Martinez, O. Sanz, B. Urones, J. Esquivias, H. Soni, R. Tasneen, S. Tyagi, S.-Y. Li, P. J. Converse, H. I. Boshoff, G. T. Robertson, G. Besra, K. A. Abrahams, A. Upton, , E. N. Jimenez

Antimicrobial Agents and Chemotherapy · Jun 21, 2022Peer-reviewedPharmacology & Toxicology

Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models

E. Nuermberger, R. Tasneen, A. Garcia, P. J. Converse, M. D. Zimmerman, V. A. Dartois, E. V. Kurbatova, A. Vernon, W. Carr, J. E. Stout, K. E. Dooley

This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.

bioRxiv · Dec 21, 2021Microbiology

Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer

P. J. Converse, D. Almeida, O. Komm, E. Nuermberger

This study evaluates the efficacy of ultrashort telacebec treatment in mouse models of Buruli ulcer, finding that total dose is more critical than duration and that resistance can emerge in immunocompromised hosts.

bioRxiv · Jun 22, 2021Microbiology

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

P. J. Converse, O. Komm, D. Almeida, T. F. Omansen, E. Nuermberger

This study evaluates the efficacy of telacebec alone and with companion drugs in reducing treatment duration for Buruli ulcer in immunocompetent and immunosuppressed mice.

bioRxiv · Jun 22, 2021 · PreprintMicrobiology

Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

R. Tasneen, D. S. Mortensen, P. J. Converse, M. E. Urbanowski, A. Upton, N. Fotouhi, E. Nuermberger, N. Hawryluk

This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.

bioRxiv · Feb 10, 2021Pathology

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

J. Xu, P. J. Converse, A. Upton, K. Mdluli, N. Fotouhi, E. Nuermberger

This study compares the efficacy of TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse tuberculosis model, finding TBAJ-587 more effective and less prone to resistance.

bioRxiv · Nov 17, 2020Microbiology

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

D. Almeida, P. J. Converse, T. F. Omansen, S. TYAGI, R. Tasneen, J. kim, E. Nuermberger

This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.

bioRxiv · Feb 10, 2020Microbiology

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

J. Xu, S.-Y. Li, D. Almeida, R. Tasneen, K. Barnes-Boyle, P. J. Converse, A. M Upton, K. Mdluli, N. Fotouhi, E. Nuermberger

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.

bioRxiv · Jan 8, 2019Pharmacology & Toxicology

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

T. F. Omansen, D. Almeida, P. J. Converse, S.-Y. Li, J. Lee, Y. Stienstra, T. S. van der Werf, J. H. Grosset, E. Nuermberger

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.

bioRxiv · Aug 19, 2018Microbiology